Literature DB >> 31497340

Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents.

Hidetomo Kikuchi1, Bo Yuan2, Xiaomei Hu3, Mari Okazaki2.   

Abstract

Cancer is a diverse class of diseases characterized by uncontrolled cell growth with the potential to invade and spread to other parts of the body, and continues to be one of the leading causes of death worldwide. Conventional cancer treatment modalities include antitumor drugs, surgical resection, locally targeted therapies such as radiation therapy. Along with improved understanding of the molecular pathogenesis of various cancers, generation and the use of smart targeted anti-cancer drugs have been challenged. The need for novel therapeutic strategies remains paramount given the sustained development of drug resistance, tumor recurrence, and metastasis. Development of new strategies aimed at improving chemotherapy sensitivity and minimizing the adverse side effects is thus essential for obtaining satisfied therapeutic outcomes for patients and enhancing their quality of life. Emerging evidence has reported that many cancer patients use either herbs employed in complementary therapies or dietary agents that influence cellular signaling worldwide. Numerous components of edible plants, collectively termed phytochemicals that have beneficial effects for health, are being reported increasingly in the scientific literature. Of those, flavonoids have attracted much attention by virtue of its wide variety of biological functions including antioxidant, anti-inflammatory, and anticancer activity. In this review, we highlight the molecular mechanisms underlying its multiple pharmacological effects, especially focusing on cancer chemoprevention. We further discuss possible strategies to develop anticancer therapy by combining flavonoids nutraceuticals and conventional chemotherapeutic agents. We also highlight numerous pharmacokinetic challenges such as bioavailability, drug-drug interactions, which are still fundamental questions concerning its future clinical application.

Entities:  

Keywords:  Cancer prevention; anticancer activity; bioavailability; combination treatment; drug transporters; drug-drug interactions; flavonoids; immunosuppression

Year:  2019        PMID: 31497340      PMCID: PMC6726994     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  105 in total

1.  Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy.

Authors:  G Zhang; Y Wang; Y Zhang; X Wan; J Li; K Liu; F Wang; K Liu; Q Liu; C Yang; P Yu; Y Huang; S Wang; P Jiang; Z Qu; J Luan; H Duan; L Zhang; A Hou; S Jin; T-C Hsieh; E Wu
Journal:  Curr Mol Med       Date:  2012-02       Impact factor: 2.222

Review 2.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.

Authors:  Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

3.  Quercetin induces necrosis and apoptosis in SCC-9 oral cancer cells.

Authors:  Maricela Haghiac; Thomas Walle
Journal:  Nutr Cancer       Date:  2005       Impact factor: 2.900

4.  Delphinidin induces necrosis in hepatocellular carcinoma cells in the presence of 3-methyladenine, an autophagy inhibitor.

Authors:  Rentian Feng; Shiow Y Wang; Ying-Hong Shi; Jia Fan; Xiao-Ming Yin
Journal:  J Agric Food Chem       Date:  2010-04-14       Impact factor: 5.279

5.  Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer.

Authors:  Takanori Maruyama; Koji Kono; Yoshiki Mizukami; Yoshihiko Kawaguchi; Kousaku Mimura; Mitsuaki Watanabe; Shinichirou Izawa; Hideki Fujii
Journal:  Cancer Sci       Date:  2010-09       Impact factor: 6.716

6.  Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.

Authors:  Jun-Shik Choi; Yong-Ji Piao; Keon Wook Kang
Journal:  Arch Pharm Res       Date:  2011-05-05       Impact factor: 4.946

7.  Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.

Authors:  Camilo E Fadul; Jan L Fisher; Jiang Gui; Thomas H Hampton; Anik L Côté; Marc S Ernstoff
Journal:  Neuro Oncol       Date:  2011-02-20       Impact factor: 12.300

8.  Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization.

Authors:  Satoshi Anai; Kathleen Shiverick; Theresa Medrano; Kogenta Nakamura; Steve Goodison; Bob D Brown; Charles J Rosser
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

9.  Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.

Authors:  Noriyoshi Iriyama; Yuta Yoshino; Bo Yuan; Akira Horikoshi; Yukio Hirabayashi; Yoshihiro Hatta; Hiroo Toyoda; Jin Takeuchi
Journal:  J Hematol Oncol       Date:  2012-01-24       Impact factor: 17.388

Review 10.  Flavonoids and the CNS.

Authors:  Anna K Jäger; Lasse Saaby
Journal:  Molecules       Date:  2011-02-10       Impact factor: 4.411

View more
  18 in total

Review 1.  Therapy-related acute myeloid leukemia and its prevention.

Authors:  Gennady Belitsky; Timur Fetisov; Kirill Kirsanov; Ekaterina Lesovaya; Olga Vlasova; Marianna Yakubovskaya
Journal:  Am J Blood Res       Date:  2020-12-15

Review 2.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

3.  Amine-Linked Flavonoids as Agents Against Cutaneous Leishmaniasis.

Authors:  Chin-Fung Chan; Zhen Liu; Iris L K Wong; Xianliang Zhao; Zaofeng Yang; Jiale Zheng; Marianne M Lee; Michael K Chan; Tak Hang Chan; Larry M C Chow
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

Review 4.  Flavonoids: structure-function and mechanisms of action and opportunities for drug development.

Authors:  Stephen Safe; Arul Jayaraman; Robert S Chapkin; Marcell Howard; Kumaravel Mohankumar; Rupesh Shrestha
Journal:  Toxicol Res       Date:  2021-01-20

5.  The Antiproliferative Effects of Flavonoid MAO Inhibitors on Prostate Cancer Cells.

Authors:  Najla O Zarmouh; Samia S Messeha; Nelly Mateeva; Madhavi Gangapuram; Kacy Flowers; Suresh V K Eyunni; Wang Zhang; Kinfe K Redda; Karam F A Soliman
Journal:  Molecules       Date:  2020-05-11       Impact factor: 4.411

Review 6.  Mechanisms of Multidrug Resistance in Cancer Chemotherapy.

Authors:  Karol Bukowski; Mateusz Kciuk; Renata Kontek
Journal:  Int J Mol Sci       Date:  2020-05-02       Impact factor: 5.923

Review 7.  Do Aspirin and Flavonoids Prevent Cancer through a Common Mechanism Involving Hydroxybenzoic Acids?-The Metabolite Hypothesis.

Authors:  Ranjini Sankaranarayanan; D Ramesh Kumar; Janki Patel; G Jayarama Bhat
Journal:  Molecules       Date:  2020-05-10       Impact factor: 4.411

Review 8.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

9.  Apigenin and Hesperidin Downregulate DNA Repair Genes in MCF-7 Breast Cancer Cells and Augment Doxorubicin Toxicity.

Authors:  Agnieszka Korga-Plewko; Monika Michalczyk; Grzegorz Adamczuk; Ewelina Humeniuk; Marta Ostrowska-Lesko; Aleksandra Jozefczyk; Magdalena Iwan; Marta Wojcik; Jaroslaw Dudka
Journal:  Molecules       Date:  2020-09-26       Impact factor: 4.411

Review 10.  Anti-neoplastic Potential of Flavonoids and Polysaccharide Phytochemicals in Glioblastoma.

Authors:  Ayesha Atiq; Ishwar Parhar
Journal:  Molecules       Date:  2020-10-23       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.